Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.
James S WilmottHussein A TawbiJohnathan A EnghNduka M AmankulorBrindha ShivalingamHiya BanerjeeIsmael A VergaraHansol LeePeter A JohanssonPeter M FergusonPhilippe SaiagCaroline RobertJean-Jacques GrobLisa H ButterfieldRichard A ScolyerJoanne M JeterGeorgina V LongMichael A DaviesPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Corticosteroid treatment was associated with reduced ICRR and PFS in COMBI-MB, similar to results with immunotherapy for MBMs. Baseline corticosteroid treatment is a key factor to consider in MBM patient management and clinical trial design/interpretation.